In summary, our data demonstrate a novel mechanism whereby the alteration of EZH2 gene copy number values enhances its tumor expression, which then epigenetically silences miR-200c expression to up-regulate BMI1-dependent hepatocarcinogenesis, providing novel therapeutic targets for an improved HCC treatment. This evidence concerns the gene EZH2 and neoplasm.